Renovo's Juvidex fails to accelerate healing of skin-graft wounds in Phase II
This article was originally published in Scrip
Executive Summary
Renovo's anti-scarring product Juvidex (mannose-6-phosphate) has failed to meet the primary endpoint of a placebo-controlled Phase II trial testing its ability to accelerate healing of skin-graft donor sites.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.